Company news
Sk Bioscience Co.,ltd. (KRX:302440) news
Sk Bioscience Co.,ltd. news releases on 6ix. Latest, Mar 18, 2026: SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT…
Press releases & updates
SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support
March 18, 2026
SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union
February 26, 2026
SK bioscience In-Licenses RSV Preventive mAb Candidate from Gates Medical Research Institute
February 3, 2026
SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family
January 28, 2026
SK bioscience, MSD, and Hilleman Laboratories Advance Zaire ebolavirus Vaccine Development with CEPI Funding
January 22, 2026
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights
November 6, 2025
SK bioscience Files for First-in-Human Trial of Universal Coronavirus Vaccine (Pan-sarbecovirus Vaccine) GBP511 Phase 1/2 study in Australia
October 15, 2025
SK bioscience Submits IND for Phase 3 Trial of 2-Dose Varicella Vaccine Reflecting Global Standard Shift
September 2, 2025
SK bioscience Discusses Further Collaboration with the Gates Foundation to Advance Global Health
August 21, 2025
Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights
August 6, 2025
SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate
July 17, 2025
SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine
May 21, 2025
IDT Biologika Accelerates Global Growth Through Strategic CDMO Partnership
May 20, 2025
SK bioscience Joins Korea's National Initiative to Develop Avian Influenza Vaccine Amid Rising Pandemic Threats
May 6, 2025
SK bioscience Expands Influenza Vaccine Exports to Southern Hemisphere Market
March 12, 2025
SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
February 25, 2025